Literature DB >> 9187112

Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.

C B Umbricht1, M Saji, W H Westra, R Udelsman, M A Zeiger, S Sukumar.   

Abstract

The inability to distinguish microinvasive follicular thyroid cancer from benign follicular tumors preoperatively presents an important surgical dilemma. We examined 44 follicular tumors and found telomerase activity in all 11 follicular carcinomas and in 8 of 33 benign follicular tumors. It was undetectable in 22 normal thyroid tissues adjacent to the tumors. Telomerase activity may thus provide a diagnostic marker distinguishing benign from malignant follicular thyroid tumors. The ability to identify invasive follicular thyroid tumors could avert over 14,000 thyroidectomies annually in the United States, thereby significantly decreasing morbidity and health care costs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187112

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.

Authors:  Sheng-Lan Wang; Wan-Tzu Chen; Ming-Tsang Wu; Hon-Man Chan; Sheau-Fang Yang; Chee-Yin Chai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

Review 4.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

5.  Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents.

Authors:  A M Straight; A Patel; C Fenton; C Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

6.  Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Authors:  Yongchun Wang; Alan K Meeker; Jeanne Kowalski; Hua-Ling Tsai; Helina Somervell; Christopher Heaphy; Lauren E Sangenario; Nijaguna Prasad; William H Westra; Martha A Zeiger; Christopher B Umbricht
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

7.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Authors:  Iñigo Landa; Ian Ganly; Timothy A Chan; Norisato Mitsutake; Michiko Matsuse; Tihana Ibrahimpasic; Ronald A Ghossein; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-07-05       Impact factor: 5.958

8.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

9.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

Review 10.  TERT promoter mutations in thyroid cancer.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2016-01-05       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.